In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF-β in the lung

Thorax

Volumn 61, Issue 10, 2006, Pages 886-894

  Nakagome, K ^a   Dohi, M ^a   Okunishi, K ^a   Tanaka, R ^a   Miyazaki, J ^b   Yamamoto, K ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; HYDROXYPROLINE; INTEGRIN; INTERLEUKIN 10; RINGER SOLUTION; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; EX VIVO STUDY; GENE REPRESSION; GENE TARGETING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LUNG; LUNG ALVEOLUS MACROPHAGE; LUNG FIBROSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING;

ANIMALS; BLEOMYCIN; BRONCHOALVEOLAR LAVAGE FLUID; CELL LINE; GENE THERAPY; GENE TRANSFER TECHNIQUES; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHA6; INTERLEUKIN-10; MACROPHAGES, ALVEOLAR; MALE; MICE; MICE, INBRED C57BL; PLASMIDS; PULMONARY FIBROSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 33750017364     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2005.056317     Document Type: Article

References (40)

1. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001;345:517-25.
2. King TE Jr, Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001;164:1025-32.
3. Collard HR, Ryu JH, Douglas WW, et al. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest 2004;125:2169-74.
4. Thannickal VJ, Toews GB, White ES, et al. Mechanisms of pulmonary fibrosis. Annu Rev Med 2004;55:395-417.
5. Chapman HA. Disorders of lung matrix remodeling. J Clin Invest 2004;113:148-57.
6. Selman M, Thannickal VJ, Pardo A, et al. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs 2004;64:405-30.
7. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125-33.
8. Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999;159:1061-9.
9. Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor β on bleomycin induced accumulation of lung collagen in mice. Thorax 1993;48:959-66.
10. Wang Q, Wang Y, Hyde DM, et al. Reduction of bleomycin induced lung fibrosis by transforming growth factor β soluble receptor in hamsters. Thorax 1999;54:805-12.
11. Nakao A, Fujii M, Matsumura R, et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 1999;104:5-11.
12. Dohi M, Hasegawa T, Yamamoto K, et al. Hepatocyte growth factor attenuates collagen accumulation in a murine model of pulmonary fibrosis. Am J Respir Crit Care Med 2000;162:2302-7.
13. Chua F, Gauldie J, Laurent GJ. Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol 2005;33:9-13.
14. Borzone G, Moreno R, Urrea R, et al. Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001;163:1648-53.
15. Gorelik L, Flavell RA. Transforming growth factor-β in T-cell biology. Nat Rev Immunol 2002;2:46-53.
16. Bartram U, Speer CP. The role of transforming growth factor β in lung development and disease. Chest 2004;125:754-65.
17. 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 1991;88:6642-6.
18. Kaminski N, Allard JD, Pittet JF, et al. Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci USA 2000;97:1778-83.
19. 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999;96:319-28.
20. 1 in vivo. Cell 1998;93:1159-70.
21. 1 secreted by rat alveolar macrophages after in vivo bleomycin injury. Am J Respir Cell Mol Biol 1996;15:252-9.
22. Cho JY, Miller M, Boek KJ, et al. Inhibition of airway remodeling in IL-5-deficient mice. J Clin Invest 2004;113:551-60.
23. Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.
24. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 1997;113:383-9.
25. Asadullah K, Sterry W, Stephanek K, et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998;101:783-94.
26. Freeburn RW, Armstrong L, Millar AB. Cultured alveolar macrophages from patients with idiopathic pulmonary fibrosis (IPF) show dysregulation of lipopolysaccharide-induced tumor necrosis factor-α (TNF-α) and interleukin-10 (IL-10) inductions. Eur Cytokine Netw 2005;16:5-16.
27. Martinez JA, King TE Jr, Brown K, et al. Increased expression of the interleukin-10 gene by alveolar macrophages in interstitial lung disease. Am J Physiol 1997;273:L676-83.
28. Kradin RL, Sakamoto H, Jain F, et al. IL-10 inhibits inflammation but does not affect fibrosis in the pulmonary response to bleomycin. Exp Mol Pathol 2004;76:205-11.
29. 1-mediated fibrosis. J Exp Med 2003;198:1179-88.
30. Arai T, Abe K, Matsuoka H, et al. Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. Am J Physiol Lung Cell Mol Physiol 2000;278:L914-22.
31. Jiang J, Yamato E, Miyazaki J. Intravenous delivery of naked plasmid DNA for in vivo cytokine expression. Biochem Biophys Res Commun 2001;289:1088-92.
32. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991;108:193-9.
33. Nakagome K, Dohi M, Okunishi K, et al. In vivo IL-10 gene delivery suppresses airway eosinophilia and hyperreactivity by down-regulating APC functions and migration without impairing the antigen-specific systemic immune response in a mouse model of allergic airway inflammation. J Immunol 2005;174:6955-66.
34. Okunishi K, Dohi M, Nakagome K, et al. A novel role of cysteinyl leukotrienes to promote dendritic cell activation in the antigen-induced immune responses in the lung. J Immunol 2004;173:6393-402.
35. Tanino Y, Makita H, Miyamoto K, et al. Role of macrophage migration inhibitory factor in bleomycin-induced lung injury and fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2002;283:L156-62.
36. Tran PL, Weinbach J, Opolon P, et al. Prevention of bleomycin-induced pulmonary fibrosis after adenovirus-mediated transfer of the bacterial bleomycin resistance gene. J Clin Invest 1997;99:608-17.
37. Khalil N, Whitman C, Zuo L, et al. Regulation of alveolar macrophage transforming growth factor-β secretion by corticosteroids in bleomycin-induced pulmonary inflammation in the rat. J Clin Invest 1993;92:1812-8.
38. Fernandez S, Jose P, Avdiushko MG, et al. Inhibition of IL-10 receptor function in alveolar macrophages by Toll-like receptor agonists. J Immunol 2004;172:2613-20.
39. Avdiushko R, Hongo D, Lake-Bullock H, et al. IL-10 receptor dysfunction in macrophages during chronic inflammation. J Leukoc Biol 2001;70:624-32.
40. Sheppard O, Cohen DS, Wang A, et al. Transforming growth factor β differentially regulates expression of integrin subunits in guinea pig airway epithelial cells. J Biol Chem 1992;267:17409-14.